<small> <!– link –> <a href=http://www.biospectrumasia.com/>Biospectrum</a> <!– end-link –> </small>
<!— Start Artilce title image –>
<!— Start Artilce title image –>
<!– End Article Title Image –>
The Asset, having completed phase III successfully in the US, is a differentiated long acting NSAIDS in the multibillion dollar global OTC analgesic market. <a href="http://www.biospectrumasia.com/biospectrum/news/214409/shasun-acquires-global-rights-ibuprofen-otc">[Read more]</a>
